Scarica l'app Stockscreener
23.44
0.62%
-0.1512
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Immunovant Inc Borsa (IMVT) Ultime notizie
Immunovant's chief medical officer sells $56,782 in stock - MSN
Immunovant CEO Peter Salzmann sells $208,899 in stock - MSN
Peter Salzmann Sells 8,767 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) CFO Sells $54,761.34 in Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $56,786.89 in Stock - MarketBeat
Immunovant's chief medical officer sells $56,782 in stock By Investing.com - Investing.com Australia
Immunovant CFO Eva Renee Barnett sells $54,756 in stock By Investing.com - Investing.com Canada
Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential - Yahoo Finance
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Bank of America Issues Pessimistic Forecast for Immunovant (NASDAQ:IMVT) Stock Price - Defense World
Bank of America Has Lowered Expectations for Immunovant (NASDAQ:IMVT) Stock Price - MarketBeat
JPMorgan Chase & Co. Lowers Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
JPMorgan Chase & Co. Sells 28,586 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Receives $47.22 Average Price Target from Analysts - MarketBeat
How to Take Advantage of moves in (IMVT) - Stock Traders Daily
Insider Buying: Immunovant, Inc. (NASDAQ:IMVT) Director Buys 16,845,010 Shares of Stock - MarketBeat
Roivant sciences increases stake in Immunovant with $336.9 million purchase By Investing.com - Investing.com Nigeria
Roivant sciences increases stake in Immunovant with $336.9 million purchase - Investing.com
Immunovant to raise $450M from institutional investors - MSN
Immunovant Progresses in Autoimmune Therapy Development - TipRanks
Immunovant (NASDAQ:IMVT) Hits New 12-Month LowWhat's Next? - MarketBeat
Immunovant Raises $450 Million Through Share Purchase Agreement - TipRanks
Immunovant Announces $450 Million Private Placement - The Manila Times
Immunovant Secures Massive $450M Private Placement to Accelerate Drug Development - StockTitan
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $47.22 - MarketBeat
Q1 Earnings Estimate for Immunovant Issued By Zacks Research - Defense World
Immunovant CFO Eva Renee Barnett sells $98,930 in stock - Investing.com India
Immunovant CFO Eva Renee Barnett sells $98,930 in stock By Investing.com - Investing.com Australia
Immunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett Sells 4,105 Shares - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) CEO Peter Salzmann Sells 5,105 Shares - MarketBeat
Warm Autoimmune Hemolytic Anemia (wAIHA) Clinical - openPR
Immunovant stock hits 52-week low at $23.86 amid challenges By Investing.com - Investing.com Nigeria
Myasthenia Gravis Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen R&D, Immunovant - The Globe and Mail
Immunovant (NASDAQ:IMVT) Reaches New 52-Week LowHere's Why - MarketBeat
Immunovant stock hits 52-week low at $23.86 amid challenges - Investing.com India
Myasthenia Gravis Market Poised for Significant Growth from - openPR
(IMVT) Long Term Investment Analysis - Stock Traders Daily
Immunovant (NASDAQ:IMVT) Lowered to “Peer Perform” Rating by Wolfe Research - Defense World
Immunovant (NASDAQ:IMVT) Shares Gap DownHere's What Happened - MarketBeat
Wolfe Research Downgrades Immunovant (NASDAQ:IMVT) to Peer Perform - MarketBeat
Immunovant (NASDAQ:IMVT) Shares Up 4.1%Here's Why - MarketBeat
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth - Yahoo Finance
Immunovant stock hits 52-week low at $24.61 amid market challenges - Investing.com Canada
RSI Alert: Immunovant (IMVT) Now Oversold - Nasdaq
Immunovant stock hits 52-week low at $24.61 amid market challenges By Investing.com - Investing.com South Africa
Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study (NASDAQ:IMVT) - Seeking Alpha
1.43%
9.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):